Monday, February 3, 2025

HealthTech Quibim’s imaginative and prescient for human digital twins will get €47.9M enhance

Quibim, a Valencia-based HealthTech firm innovating the usage of imaging biomarkers for precision drugs, introduced right this moment the shut of its €47.9 million Collection A financing so as set up US presence.

The financing was led by Asabys (by means of its fund Sabadell Asabys II) and Buenavista Fairness Companions (by means of the BHG I fund, created in partnership with Columbus Enterprise Companions), and joined by GoHub Ventures and UI Investissement as new traders. It was additionally joined by present traders, Amadeus Capital Companions, APEX Ventures, Partech, Adara Ventures, Leadwind (KFund’s early development fund), Tony Fadell’s Construct Collective, and particular person investor Dr. Jonathan Milner, founding father of Abcam plc.

Quibim’s mission is to show imaging right into a catalyst for precision well being, and we’re deeply grateful to each our new and present traders for his or her help,” mentioned Dr Ángel Alberich-Bayarri, CEO and Co-founder of Quibim. “Our international enlargement into the U.S. is a important milestone as we work with pharmaceutical leaders and healthcare suppliers to unlock the facility of imaging to revolutionise diagnostics  and enhance affected person outcomes.”

Based in 2012 by Dr Ángel Alberich-Bayarri and Luis Martí Bonmatí, Quibim is devoted to the mission of unlocking a whole, non-invasive understanding of each tissue level within the human physique, at any second in time. To realize this, the corporate develops foundational AI fashions utilized to imaging that extract actionable insights from MRI, CT, and PET scans. These insights allow exact characterisation of phenotypes and prediction of outcomes in areas similar to oncology, immunology, neurology and metabolic issues.

Quibim says that is the pathway towards reaching human digital twins, dynamic fashions that not solely mirror and permit well being monitoring but additionally improve affected person stratification, enhance the success charges of drug improvement packages, and allow therapy testing earlier than utility.

Immediately, the corporate is constructing digital twins on the organ and lesion degree, exemplified by options like QP-Mind, QP-Prostate, and QP-Liver.

Nevertheless, as the quantity of whole-body scans and associated imaging knowledge continues to develop within the coming years, Quibim goals for his or her fashions to ultimately analyse your complete physique.

With over 170 installations worldwide, together with in Mass Basic Brigham and Stanford, and regulatory clearances throughout the US, EU, UK, Quibim’s expertise seems to be to bridgethe hole between analysis, scientific observe, and drug improvement.

Final 12 months, Philips introduced a world partnership with Quibim to combine its AI fashions into MR scanners, whereas the corporate additionally secured strategic alliances with main biopharma giants similar to Merck KGaA and Novartis.

Asabys is thrilled to help Quibim in reworking the imaging diagnostics area,” mentioned Guillem Masferrer, Accomplice at Asabys Companions. “Their potential to mix AI with imaging biomarker discovery addresses important unmet wants in​ oncology, neurology, and past. We’re assured that Quibim’s revolutionary options can have a profound affect on international healthcare.”

Quibim’s product portfolio consists of:

  • QP-Prostate®: the corporate’s flagship product is designed to boost prostate most cancers detection by means of an industry-leading AI-powered lesion detection.
  •  QP-Mind®: AI-based early-stage neurological illness quantification software program for quantification of early mind atrophy and lesions.
  • QP-Liver®: automated AI software for MR prognosis of diffuse liver ailments by means of correct quantification of tissue fats and iron ranges.
  •  QP-Insights®: A platform to handle, retailer and analyse multi-omics knowledge in scientific trials and real-world knowledge research. In accordance with Quibim, QP-Insights is the platform managing the biggest imaging datasets on this planet, accounting for greater than 100 million medical pictures.

With the collection A financing, Quibim will set up a powerful U.S. presence, constructing on its success in Europe, by means of strategic collaborations with hospitals and pharmaceutical firms.

Quibim’s expertise exemplifies the subsequent wave of precision drugs,” mentioned José Mesa, Accomplice at Columbus and Buenavista’s consultant on the Board. “Their spectacular monitor document with international pharmaceutical partnerships, together with partnerships with firms similar to Merck KGaA and Philips, exemplify Quibim’s position in reworking imaging knowledge into worthwhile predictions for scientific trials and therapy planning. We anticipate that as Quibim develops its pipeline of companion diagnostic instruments, we’ll see large momentum for its expertise and merchandise.”

“The foundational analysis carried out by Quibim’s crew has not solely knowledgeable {industry} requirements, but additionally led to the corporate pioneering an strategy to combining radiomics and deep studying that’s now a regular of its personal,” mentioned Pierre Socha, Accomplice at Amadeus Capital Companions. “This platform strategy was novel on the time of our first funding and proved to be the precise technique for speedy scale-up.”


Stay Tune With Fin Tips

SUBSCRIBE TO OUR NEWSLETTER AND SAVE 10% NEXT TIME YOU DINE IN

We don’t spam! Read our privacy policy for more inf

Related Articles

Latest Articles